CD47, an immune checkpoint protein expressed on malignant cells, acts as a “don’t eat me” signal by binding to signal regulatory protein alpha (SIRPα) on macrophages, enabling cells to evade phagocytosis. High CD47 expression in acute myeloid...
Introduction:Antibody-drug conjugates (ADCs), as an emerging class of targeted therapies, have garnered significant attention in cancer treatment due to their clinical potential in recent years. Currently, most ADC payloads are cytotoxic agents, prompting the need for...
Infection remains a major cause of mortality and morbidity in patients with acute myeloid leukaemia (AML) and high-risk myelodysplasia (MDS). The recent advent of venetoclax based therapies have altered the degree of immunosuppression, increasing treatment options for...
Background: nkAML accounts for 40% of all AML. Although nkAML pts are included into favorable (fav) and intermediate (int) European Leukemia Net (ELN2022) risk category, the outcome is highly heterogeneous, and poses therapeutic challenges particularly as regards...
Background: Acute myeloid leukemia (AML) with monocytic differentiation can be associated with resistance to hypomethylating agents plus venetoclax (HMA+VEN). Using a multi-modal analysis in newly diagnosed patients with AML treated with HMA+VEN, we assessed the...
Introduction:Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of abnormal hematopoietic stem and progenitor cells. TP53 mutations, present in 8-30% of AML cases, are associated with high risk of relapse and poor prognosis. To...
Recent Comments